Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients

被引：0
|
作者：
Shen, B. [1 ,2 ]
Pan, B. [1 ,2 ]
Wu, Y. [1 ,2 ]
Shi, L. [1 ,2 ]
Gao, J. [1 ,2 ]
Du, X. [1 ,2 ]
Feng, J. [1 ,2 ]
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Elderly NSCLC; Tislelizumab; First-line;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-03
引用
收藏
页码：S317 / S318
页数：2
相关论文
共 50 条
  • [31] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
    Fang, S.
    Xu, T.
    Zhao, X.
    Liu, N.
    Wang, X.
    Cheng, W.
    Fang, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
  • [32] First-Line Nivolumab Plus Ipilimumab versus Chemotherapy in NSCLC
    不详
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 465 - 465
  • [33] Triweekly Oxaliplatin Plus Oral Capecitabine as First-Line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
    Dong, Ningning
    Jiang, Wanrong
    Li, Huiqing
    Liu, Zhifang
    Xu, Xiaoqing
    Wang, Mingyu
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (06): : 559 - 563
  • [34] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [35] Treatment of anemia in elderly patients receiving first-line chemotherapy for advanced lung cancer: Analysis of an unselected population
    Mansueto, G
    Gareri, R
    Buccilli, A
    Trapasso, T
    Giampaolo, M
    Gamucci, T
    [J]. LUNG CANCER, 2005, 49 : S257 - S257
  • [36] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [37] First-line single agent treatment with gefitinib in patients with advanced NSCLC
    Brossart, Peter
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (08) : 490 - 491
  • [38] Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
    Ren, Xiang
    Tian, Yiqun
    Wang, Zhixian
    Wang, Jing
    Li, Xing
    Yin, Yisheng
    Chen, Ruibao
    Zhan, Ying
    Zeng, Xiaoyong
    [J]. BMC UROLOGY, 2022, 22 (01)
  • [39] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
    Qiu, Hai-Bo
    [J]. THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
  • [40] Docetaxel and cisplatin as first-line chemotherapy in advanced NSCLC.
    Behera, D
    Aggarwal, AN
    Gupta, D
    Jindal, SK
    Sharma, SC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 705S - 705S
12345